Skip to main content
Sign In

You have reached the Web site for the Department of Pathology at the University of Colorado Denver.

The Graduate School at UC Denver
 

Cancer Biology Program

Graduate Training in Biomedical Research Leading to a Ph.D.


​Faculty

  
Research Interest
Steve Anderson, PhD
My lab is interested in signaling pathways that regulate mammary gland development and tumorigenesis
David Bentley, PhD
Our research asks how the RNA polymerase II transcriptional machinery and RNA processing factors work together to achieve coordinated synthesis and maturation of messenger RNA (mRNA).
Andrew Bradford, PhD
My research interests focus on hormone/growth factor signaling and cancer
Diana Cittelly, PhD

​Deciphering the mechanisms underlying increased risk of brain metastases in young women with triple negative breast cancer. These include ovarian estrogen effects on reactive astrocytes that results in paracrine activation of EGFR and TRKB signaling in brain metastatic cells.

James Costello, PhD
Within the broad scope of systems biology, my lab focuses on 3 research areas: 1) Network inference for identifying drug targets, 2) Predicting drug sensitivity from -omics datasets, and 3) Modeling temporal effects of drug combinations
Scott Cramer PhD
Prostate Cancer Tumor Suppressors, Stem Cells, Tumor Initiating cells, Signal Transduction, Receptor Signaling
James DeGregori, PhD
Studies to better understand the conditions that foster the initiation of leukemias and lymphomas are currently a major thrust of the lab
Jorge DiPaola, MD

​The DiPaola laboratory dedicates all efforts to scientific and clinical problems related to the effect that critical components of the hemostatic system, such as platelets and coagulation factors, have on human disease... Our ultimate hope is that through research we can contribute to the improvement of lives of individuals with bleeding and thrombotic disorders

Robert Doebele, MD, PhD
The overall focus of my laboratory is the study of oncogenic gene fusions in lung cancer including ALK, ROS1, RET and NTRK1
Joaquin Espinosa, Ph.D.
​Our main research goal is to understand how gene networks control cell behavior in homeostasis and human disease. Our two main focus areas are cancer biology and Down syndrome.
Lauren Fishbein, MD, PhD

​My research interests are to understand what causes neuroendocrine tumors to form (pheochromocytomas, paragangliomas, gastrointestinal and pancreatic neuroendocrine tumors). I am particularly interested in studying the inherited and tumor specific genetic changes that lead to tumor formation. The long terms goals of my research are to identify markers to predict aggressive or metastatic disease which can ultimately be used to develop therapies for prevention and/or treatment of these tumors.

Heide Ford, PhD
Our laboratory focuses on a specific family of homeoproteins, the Six family, and their transcriptional cofactors, Eya and Dach. The Six1 homeobox gene is overexpressed in 50% of primary breast cancers and 90% of metastatic lesions, and its overexpression
Mayumi Fujita, MD, PhD

​The main focus of our current research is: (1) to understand subpopulations of cancer cells, such as cancer stem cells from human melanoma, (2) to study biological roles of inflammatory or anti-inflammatory molecules (particularly IL-1, IL-37 and AAT, inflammasome components) in the progression of human malignant melanoma, (3) to understand biological roles of a new cytokine, IL-37, (4) to identify melanoma-related and host response-related biomarker profiling from blood of melanoma patients, and (5) to identify metastasis-related genetic/genomic changes in human melanoma.  The experiments utilize in vitro methodologies (cellular and molecular biology, immunology, pathology) and in vivo animal study (xenotransplantation, direct in vivo xenograft and genetically-engineered mouse models).

Arthur Gutierrez-Hartmann, MD
Dr. Gutierrez-Hartmann’s laboratory focuses on two main projects: (1) elucidating the molecular mechanisms governing pituitary-specific gene expression; and, (2) determining the role of Ets transcription factors in breast cancer.
Bryan Haugen, MD
Thyroid Diseases; Endocrine Neoplasms
Lynn Heasley, PhD
My lab investigates autocrine and paracrine signaling through receptor tyrosine kinases, both as oncogene drivers and as acquired or intrinsic resistance mechanisms to targeted therapeutics
Cheng-Jun Hu, PhD
To distinguish the role of HIF-1a and HIF-2a in cancer progression, our work has been focusing on these specific areas:
Paul Jedlicka, MD, PhD
Currently, our laboratory is broadly interested in further understanding the biology of Jumonji-domain histone demethylases in regulation of gene expression and cancer phenotypes in Ewing Sarcoma
Antonio Jimeno MD
He has made a special emphasis in 1) developing better preclinical models, 2) determining predictors of response, and 3) devising ways to integrate that knowledge into clinical trials to individualize anti-cancer therapy.
Craig Jordan, PhD

​Dr. Jordan serves as the Chief of the Hematology Division and directs a research program focused on the development of novel therapies for the treatment of leukemia.

Sana Karam, M.D/Ph.D.
Dr. K​aram’s laboratory is focused on basic and translational research related to head and neck and CNS cancer
Robert Keith, MD

​Dr. Keith's main research interest is lung cancer chemoprevention and early detection. He was Principal Investigator (PI) of the NCI-sponsored Lung Cancer Biomarkers and Chemoprevention Consortium (LCBCC) Iloprost Chemoprevention Trial and is the PI of an ongoing VA lung cancer chemoprevention trial evaluating pioglitazone in high risk current and former smokers. He is also the co-PI on a recently initiated chemoprevention trial examining inhaled iloprost.

James Lambert, PhD
The role of prostate derived factor in prostatic inflammation and tumorigenicity
Bolin Liu, MD
Our primary research interests focus on erbB receptor tyrosine kinases (RTKs)-mediated signal transduction in breast cancer and miRNA-mediated epigenetic regulation of drug resistance and metastasis
Shi-Long Lu, MD, PhD
Role of PI3K/PTEN/AKT pathway in HNSCC progression.
M. Scott Lucia, MD
Director, Prostate Diagnostic Laboratory
Traci Lyons, PhD

​Dr. Lyons laboratory focuses on mechanisms of lymphatic mediated metastasis of breast cancer.  Specifically, utilizing mouse models to investigate developmentally regulated programs of inflammation and lymphangiogenesis that are utilized in the adult mammary gland and may be hijacked by breast tumor cells. The results of these translational studies have the potential to instruct therapy aimed at prevention of breast cancer metastasis.

Stephen Malkoski, MD, PhD
I am interested in the identification of cancer stem cells in lung squamous cell carcinoma and targeting of these stem cells in preclinical chemotherapeutic trials
Raphael Nemenoff, PhD
My laboratory is focused on examining molecular pathways that regulate the progression and metastasis of lung cancer.
David Orlicky, PhD
The study of lipid accumulation in non-adipocytes and how that process is regulated in multiple tissues, and in normal and pathologic situations
1 - 30Next

© The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.